Fibrin stabilization (factor XIII), fibrin structure and thrombosis

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue 5-6, 2003, Pages 430-437

  Bereczky, Zsuzsanna ^a   Katona, Éva ^a   Muszbek, László ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Factor XIII; Factor XIII A Val34Leu polymorphism; Fibrinolysis; Thrombosis

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 13; CALCIUM ION; ENZYME PRECURSOR; FIBRIN; PROTEIN SUBUNIT; THROMBIN;

ALLELE; ALPHA CHAIN; ARTERY DISEASE; ARTERY THROMBOSIS; BIOCHEMISTRY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CROSS LINKING; DEEP VEIN THROMBOSIS; FIBRIN CLOT; FIBRINOLYSIS; GENE FUNCTION; GENETIC POLYMORPHISM; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; RISK ASSESSMENT; STROKE; THROMBOSIS; VEIN THROMBOSIS;

FACTOR XIII; FIBRIN; HUMANS; POLYMORPHISM, GENETIC; THROMBOSIS;

EID: 14044254083     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083841     Document Type: Conference Paper

References (108)

1. Muszbek L, Ádány R, Mikkola H. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation and function. Crit Rev Lab Sci 1996;33:357-421.
2. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999;94:271-305.
3. Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing γ-chains. Biochemistry 1996;35:10448-10453.
4. Lorand L, Losowsky MS, Miloszewski KJM. Human Factor XIII: Fibrin-stabilizing factor. Progr Haemost Thromb 1980;5:245-290.
5. Board PG, Losowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency. Blood Rev 1993;7:229-242.
6. Inbal A, Muszbek L. Coagulation factor deficiencies and pregnancy loss. Semin Thromb Hemost 2003;29:171-174.
7. Seitz R, Duckert F, Lopaciuk S, Muszbek L, Rodeghiero F, Seligsohn U. ETRO Working Party on factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Sem Thromb Hemost 1996;22:415-418.
8. Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999;107:468-484.
9. Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost 2001;86:57-65.
10. Koseki S, Souri M, Koga S, Yamakawa M, Shitishima T, Maruyama Y, Yanai F, Ichinose A. Truncated mutant B subunit for factor XIII causes its deficiency due to impaired intracellular transportation. Blood 2001;97:2667-2672.
11. Lorand L, Jacobsen A. Accelerated lysis of blood clots. Nature 1962;195:911-912.
12. Gormsen J, Fletcher AP, Alkjaersig N, Sherry S. Enzymatic lysis of plasma clots: The influence of fibrin stabilization on lysis rates. Arch Biochem Biophys 1967;120:654-665.
13. Henderson KW, Nussbaum M. The mechanism of enhanced streptokinase induced clot lysis following in-vitro factor XIII inactivation. Br J Haemat 1969;17:445-453.
14. McDonagh RP, McDonagh J, Duckert F.The influence of fibrin crosslinking on the kinetics of urokinase-induced clot lysis. Br J Haematol 1971;21:323-332.
15. Schwartz ML, Pizzo SV, Hill RI, McKee PA. The effect of fibrin-stabilizing factor on the subunit structure of human fibrin. J Clin Invest 1971;50:1506-1513.
16. Gaffney PJ, Whitaker AN. Fibrin crosslinks and lysis rates. Thromb Res 1979;14:85-94.
17. Jansen JWCM, Haverkate F, Koopman J, Nieuwenhuis HK, Kluft C, Boschman TAC. Influence of factor XIIIa activity on human whole blood clot lysis in vitro. Thrombos Haemost 1987;57:171-175.
18. Leidy EM, Stern AM, Friedman PA, Bush LR. Enhanced thrombolysis by a factor XIIIa inhibitor in a rabbit model of femoral artery thrombosis. Thromb Res 1990;59:15-26.
19. Shebuski RJ, Sitko GR, Claremon DA, Baldwin JJ, Remy DC, Stern AM. Inhibition of factor XIIIa in a canine model of coronary thrombosis: Effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood 1990;75:1455145-1455149.
20. Reed GL, Houng AK. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Circulation 1999;99:299-304.
21. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann NY Acad Sci 2001;936:11-30.
22. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann NY Acad Sci 2001;936:291-311.
23. Mosesson MW. Fibrinogen γ chain functions. J Thromb Haemost 2003;1:231-238.
24. Mosesson MW, Siebenlist KR, Amrani DL, DiOrio JP. Identification of covalently linked trimeric and tetrameric D domains in crosslinked fibrin. Proc Natl Acad Sci USA 1989;86:1113-1117.
25. Shainoff JR, Urbanic DA, DiBello PM. Immunoelectrophoretic characterizations of the cross-linking of fibrinogen and fibrin by factor XIIIa and tissue transglutaminase. J Biol Chem 1991;266:6429-6437.
26. Siebenlist KR, Meh D, Mosesson MW. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb Haemost 2001;86:1221-1228.
27. Siebenlist KR, Mosesson MW. Factors affecting γ-chain multimer formation in cross-linked fibrin. Biochemistry 1992;31:936-941.
28. Sakata Y, Aoki N. Crosslinking of α2-plasmin inhibitor to fibrin by fibrin- stabilizing factor. J Clin Invest 1980;65:290-297.
29. Tamaki T, Aoki N. Cross-linking of α2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. Biochim Biophys Acta 1981;661:280-286.
30. Ichinose A, Aoki N. Reversible crosslinking of α2-plasmin inhibitor to fibrinogen by fibrin-stabilizing factor. Biochim Biophys Acta 1982;706:158-164.
31. Aoki N, Harpel PL: Inhibitors of the fibrinolytic enzyme system. Sem Thromb Haemost 1984;10:24-41.
32. Sumi Y, Ichikawa Y, Nakamura Y, Miura O, Aoki N. Expression and characterisation of pro α2-plasmin inhibitor. J Biochem 1989;106:703-707.
33. Bangert K, Johnsen AH, Christensen U, Thorsen S. Different N-terminal forms of α2-plasmin inhibitor in human plasma. Biochem J 1993;291:623-625.
34. Lee KN, Jackson KW, Christiansen VJ, Chung KH, McKee PA. A novel plasma proteinase potentiates α2-antiplasmin inhibition of fibrin digestion. Blood 2004;103:3783-3788.
35. Francis CW, Marder VJ. Increased resistance to plasmic degradation of fibrin with highly crosslinked α-polymer chains formed at high factor XIII concentrations. Blood 1988;71:1361-1365.
36. Siebenlist KR, Mosesson MW. Progressive crosslinking of fibrin γ chains increases resistance to fibrinolysis. J Biol Chem 1994;269:28414-28419.
37. Sakata Y, Mimuro J, Aoki N. Differential binding of plasminogen to crosslinked and non-crosslinked fibrin: its significance in hemostatic defect in factor XIII deficiency. Blood 1984;63:1393-1401.
38. Folk JA, Finlayson JS. The epsilon(γ-glutamyl) lysine crosslink and the catalytic role of transglutaminases. Adv Protein Chem 1977;31:1-133.
39. Haverkate F. Lysis of crosslinked and non-crosslinked purified fibrin. Thromb Diath Haemorrh 1975;34:584-585.
40. Kimura S, Tamaki T, Aoki N. Acceleration of fibrinolysis by the amino-terminal peptide of α2-plasmin inhibitor. Blood 1985;66:157-160.
41. Lee KN, Lee SC, Jackson KW, Tae WC, Schwartzott DG, McKee PA. Effect of phenylglyoxal-modified α2-antiplasmin on urokinase-induced fibrinolysis. Thromb Haemost 1998;80:637-644.
42. Lee KN, Tae WC, Jackson KW, Kwon SH, McKee PA. Characterization of wild-type and mutant α2-antiplasmins: fibrinolysis enhancement by reactive site mutant. Blood 1999;94:164-171.
43. McDonagh J, Fukue H. Determinants of substrate specifity for factor XIII. Sem Thromb Haemost 1996;22:369-376.
44. Hevessy Z, Haramura G, Boda Z, Udvardy M, Muszbek L. The role of platelet factor XIII in fibrin-alpha-2-antiplasmin crosslinking. Thromb Haemost 1996;75:161-167.
45. Bendixen E, Borth W, Harpel PC. Transglutaminases catalyze cross-linking of plasminogen to fibronectin and human endothelial cells. J Biol Chem 1993;268:21962-21967.
46. Bendixen E, Harpel PC, Sottrup-Jensen L. Location of the major epsilon-(gamma-glutamyl) lysyl cross-linking site in transglutaminase modified human plasminogen. J Biol Chem 1995;270:17929-17933.
47. Valnickova Z, Enghild JJ. Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. J Biol Chem 1998;273:27220-27224.
48. Jansen PH, Lorand L, Ebbesen P, Gliemann J: Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Eur J Biochem 1993;214:141-146.
49. Ritchie H, Jamieson A, Booth NA. Thrombin modulates synthesis of plasminogen activator inhibitor 2 (PAI-2) by human peripheral blood monocytes. Blood 1995;86:3428-3435.
50. Ritchie H, Robbie LA, Kinghom S, Exley R, Booth NA. Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin. Thromb Haemost 1999;81:96-103.
51. Ádány R, Szegedi A, Ablin RJ, Muszbek L. Fibrinolysis resistant fibrin deposits in lymph nodes with Hodgkin's disease. Thromb Haemost 1988;60:293-297.
52. Muszbek L, Ádány R. Intratumoral fibrin stabilization. In: Nigam SK, McBrien DCH, Slater TF, editors. Lipid peroxidation and cancer. Berlin: Springer Verlag; 1988. p. 339-349.
53. Dvorak HF, Harvey S, McDonagh J. Quantitation of fibrinogen influx and fibrin deposition and turnover in line 1 and line 10 guinea pig carcinomas. Cancer Res 1984;44:3348-3354.
54. Zacharski LR, Brown FE, Memoli WA, Kisiel W, Kudryk BJ, Rousseau SM, Hunt JA, Dunwiddie C, Nutt AM. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immun Immunopathol 1992;63:155-162.
55. Carmassi F, de Negri F, Morale M, Song KY, Chung SI. Fibrin degradation in the synovial fluid of rheumatoid arthritis patients: a model for extravascular fibrinolysis. Semin Thromb Haemost 1996;22:489-496.
56. Ádány R, Nemes Z, Muszbek L. Characterization of Factor XIII containing macrophages in lymph nodes with Hodgkin's disease. Br J Cancer 1987;55:421-426.
57. Kohler HP, Ariens RAS, Whitaker P, Grant PJ. A common coding polymorphism in the factor XIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity. Thormb Haemost 1998;80:704.
58. Wilmer M, Rudin K, Kolde HJ, Poetzsch B, Lenz W, Moessmer G, Meili E, Egbring R, Gempeler-Messina P, Gempeler M, Bastian S, Kohler HP. Evaluation of a sensitive colorimetric FXIII incorporation assay. Effects of FXIII Val34Leu, plasma fibrinogen concentration and congenital FXIII deficiency. Thromb Res 2001;102:81-91.
59. Muszbek L. Deficiency causing mutations and common polymorphisms in the factor XIII-A gene. Thromb Haemost 2000;84:524-527.
60. Kohler HP, Ariens RA, Mansfield MW, Whitaker P, Grant PJ. Factor XIII activity and antigen levels in patients with coronary artery disease. Thromb Haemost 2001;85:569-570.
61. Mills JD, Mansfield MW, Grant PJ. Factor XIII - circulating levels and the Val34Leu polymorphism in the healthy male relatives of patients with severe coronary artery disease. Thromb Haemost 2002;87:409-414.
62. Kakko S, Elo T, Tapanainen JM, Huikuri HV, Savolainen MJ. Polymorphisms of genes affecting thrombosis and risk of myocardial infarction. Eur J Clin Invest 2002;32:643-648.
63. Chatterjee T, Schroeder V, Windecker S, Meier B, Kohler HP: Venous and intracoronary factor XIII A-subunit antigen and activity levels are not associated with extent of coronary artery disease. J Thromb Haemost 2003;1:861-863.
64. Kohler HP, Ariens RA, Catto AJ, Carter AM, Miller GJ, Cooper JA, Mansfield MW, Standeven KF, Grant PJ. Factor XIII A-subunit concentration predicts outcome in stroke subjects and vascular outcome in healthy, middle-age men. Br J Haematol 2002;118:825-832.
65. Alkjaersig N, Fletcher AP, Lewis M, Itterah R. Reduction of coagulation factor XIII concentration in patients with myocardial infarction, cerebral infarction, and other thromboembolic disorders. Thromb Haemost 1977;38:863-873.
66. Knudsen JB, Gormsen J, Skagen K, Amtorp O. Changes in platelet functions, coagulation and fibrinolysis in uncomplicated cases of acute myocardial infarction. Thromb Haemost 1980;42:1513-1522.
67. Kloczko J, Wojtukiewicz M, Bielawiec M, Zuch A. Alteration of haemostasis parameters with special reference to fibrin stabilization, factor XIII and fibronectin in patients with obliterative atherosclerosis. Thromb Res 1988;51:575-581.
68. Kloczko J, Wojtukiewicz M, Bielawiec M, Zarzycka B, Kinalska I. Plasma factor XIII and some other haemostasis parameters in patients with diabetic angiopathy. Acta Haemat 1986;76:81-85.
69. Kloczko J, Wojtukiewicz M, Bielawiec M. Molecular subunits and transamidase activity of factor XIII in patients with deep vein thrombosis. Folia Haematol 1986;113:810-814.
70. van Hylckama Vlieg A, Komanasin N, Ariëns RA, Poort SR, Grant PJ, Bertina RM, Rosendaal FR: Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol 2002;119:169-175.
71. Mikkola H, Syrjälä M, Rasi V, Vahtera E, Peltonen L, Palotie A. Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood 1994;84:517-525.
72. Balogh I, Szôke G, Kárpáti L, Wartiovaara U, Katona É, Komáromi I, Haramura G, Pfliegler G, Mikkola H, Muszbek L. Val34Leu polymorphism of plasma FXIII: biochemistry and epidemiology in familial thrombophilia. Blood 2000;96:2479-2486.
73. Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant P. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998;79:8-13.
74. Wartiovaara U, Perola M, Mikkola H, Tötterman K, Savolainen V, Penttilä A, Grant PJ, Tikkanen MJ, Vartiainen E, Karhunen PJ, Peltonen L, Palotie A. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis 1999;142:295-300.
75. Elbaz A, Poirier O, Canaple S, Chédru F, Cambien F, Amarenco P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000;95:586-591.
76. Canavay I, Henry M, Morange PE, Tiret L, Poirier O, Ebagosti A, Bory M, Julian-Vague I. Genetic polymorphisms and coronary artery disease in the South of France. Thromb Haemost 2000;83:212-216.
77. Franco RF, Reitsma PH, Lourenco D, Maffei FH, Morelli V, Tavella MH, Araújo AG, Piccinato CE, Zago MA. Factor XIII Val34Leu is a genetic factor involved in the aetiology of venous thrombosis. Thromb Haemost 1999;81:676-679.
78. Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998;92:2766-2770.
79. McCormack LJ, Kain K, Catto AJ, Kohler HP, Stickland MH, Grant PJ. Prevalence of FXIII V43L in populations with different cardiovascular risk. Thromb Haemost 1998;80:523-524.
80. Kohler HP, Futers TS, Grant PJ. Prevalence of three common polymorphisms in the A-subunit gene of factor XIII in patients with coronary artery disease. Thromb Haemost 1999;81:511-515.
81. Attié-Castro FA, Zago MA, Lavinha J, Elion J, Rodriguez-Delfin L, Guerreiro JF, Franco RF. Ethnic heterogeneity of the factor XIII Val34Leu polymorphism. Thromb Haemost 2000;84:601-603.
82. Suzuki K, Henke J, Iwata M, Henke L, Tsuji H, Fukunaga T, Ishimoto G, Szekelyi M, Ito S. Novel polymorphisms and haplotypes in the human coagulation factor XIII A-subunit gene. Human Genetics 1996;98:393-395.
83. Wartiovaara U, Mikkola H, Szôke G, Haramura G, Kárpá ti L, Balogh I, Lassila R, Muszbek L, Palotie A. Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. Thromb Haemost 2000;84:595-600.
84. Ariens RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymporhism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000;96:988-995.
85. Schröder V, Kohler HP. Effect of factor XIII Val34Leu on α2-antiplasmin incorporation into fibrin. Thromb Haemost 2000;84:1128-1130.
86. Schroeder V, Chatterjee T, Kohler HP. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thromboelastography. Thromb Res 2001;104:467-474.
87. Muszbek L, Bereczky Z, Katona É. Blood coagulation Factor XIII: Involvement in fibrinolysis and thrombosis; in Arnout J, de Gaetano G, Hoylaerts M, Peerlinck K, Van Geet C, Verhaeghe R (ed): Thrombosis: Fundamentals and clinical aspects. Leuven, Leuven University Press, 2003, pp 197-224.
88. Franco RF, Pazin-Filho A, Tavella AH, Simoes MV, Marin-Neto JA, Zago MA. Factor XIII Val34Leu and the risk of myocardial infarction. Haematologica 2000;85:67-71.
89. Gemmati D, Serino ML, Ongaro A, Tognazzo S, Moratelli S, Resca R, Moretti M, Scapoli GL. A common mutation in the gene for coagulation factor XIII-A (Val34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am J Hematol 2001;67:183-188.
90. Corral J, González-Conejero R, Iniesta JA, Riviera J, Martínez C, Vicente V. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica 2000;85:293-297.
91. Roldan V, Corral J, Marin F, Rivera J, Pineda J, González-Conejero R, Sogorb F, Vicente V. Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction. Am J Cardiol 2003;91:1242-1245.
92. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003;107:1117-1122.
93. Aleksic N, Ahn C, Wang YW, Juneja H, Folsom AR, Boerwinkle E, Wu KK. Factor XIIIA Val34Leu polymorphism does not predict risk of coronary artery disease: the atherosclerosis risk in communities (ARIC) study. Arterioscler Thromb Vasc Biol 2002;22:348-352.
94. Butt C, Zheng H, Randell E, Robb D, Parfrey P, Xie YG. Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction. Blood 2003;101:3037-3041.
95. Reiner AP, Frank MB, Schwartz SM, Linenberger ML, Longstreth WT, Teramura G, Rosendaal FR, Psaty BM, Siscovick DS. Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women. Br J Haematol 2002;116:376-382.
96. Roldán V, Corral J, Marín F, Rivera J, Vicente V. Effect of factor XIII Val34Leu polymorphism on thrombolytic therapy in premature myocardial infarction. Thormb Haemost 2002;88:354-355.
97. Reiner AP, Heckbert SR, Vos HL, Ariëns RA, Lemaitre RN, Smith NL, Lumley T, Rea TD, Hindorff LA, Schellenbaum GD, Rosendaal FR, Siscovick DS, Psaty BM. Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. Blood 2003;102:25-30.
98. He JQ, Gaur LK, Stempien-Otero A, Nelson K, Levy WC, O'Brien KD, Bolgiano DC, Reiner AP: Genetic variants of the hemostatic system and development of transplant coronary artery disease. J Heart Lung Transplant 2002;21:629-636.
99. Renner W, Brodmann M, Pabst E, Stanger O, Wascher TC, Pilger E. The V34L polymorphism of factor XIII and peripheral arterial disease. Int Angiol 2002;21:53-57.
100. Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ: Factor XIII Val34Leu. A novel association with primary intracerebral hemorrhage. Stroke 1998;29:813-816.
101. Iniesta JA, Corral I, González-Conejero R, Díaz Ortuno A, Martinez Navarro ML, Vicente V: Role of factor XIII Val34Leu polymorphism in patients with migraine. Cephalalgia 2001;21:837-841.
102. Endler G, Funk M, Haering D, Lalouschek W, Lang W, Mirafzal M, Wagner O, Mannhalter C. Is the factor XIII 34Val/Leu polymorphism a protective factor for cerebrovascular disease? Br J Haematol 2003;120:310-314.
103. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999;93:906-908.
104. Renner W, Köppel H, Hoffmann C. Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria. Thromb Res 2000;99:35-39.
105. Alhenc-Gelas M, Reny JL, Aubry ML, Aiach M, Emmerich J: The FXIII Val34Leu mutation and the risk of venous thrombosis. Thromb Haemost 2000;84:1117-1118.
106. Margaglione M, Bossone A, Brancaccio V, Ciampa A, Di Minno G. Factor XIII Val34Leu polymorphism and risk of deep vein thrombosis. Thromb Haemost 2000;84:1118-1119.
107. Ramacciotti E, Wolosker N, Puech-Leao P, Zeratti EA, Gusson PR, del Giglio A, Franco RF. Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res 2003;109:171-174.
108. Francis CW. Factor XIII polymorphisms and venous thromboembolism. Arch Pathol Lab Med 2002;126:1391-1393.